Lovisenberg Diakonale Sykehus: Covid-19 report in Qlik and NPrinting
Case
Lovisenberg Diakonale Sykehus and twoday have been working together for an extended period to develop applications in QlikView.
When the coronavirus hit Norway in full force, the needs changed, and there was a redirection of resources within data analysis.
The hospital and health authorities wanted daily reporting on the disease's progression. Lovisenberg Diakonale Sykehus needed therefore to automate this work as much as possible. twoday was tasked with the development of the reporting.
/En%20dame%20og%20en%20mann%20sitter%20p%C3%A5%20en%20kafe%20med%20gule%20stoler%20og%20jobber.jpg?width=1280&height=1000&name=En%20dame%20og%20en%20mann%20sitter%20p%C3%A5%20en%20kafe%20med%20gule%20stoler%20og%20jobber.jpg)
The solution
The health authorities needed reliable figures on the progression of the disease on a daily basis. Initially, Lovisenberg Diakonale Sykehus manually recorded the disease numbers. Therefore, there was a need for an efficient and automatic solution. twoday developed an application that could report the disease numbers every day in an automatically generated report. The application is developed in QlikView and reported through NPrinting, an add-on tool for Qlik. Two applications have been developed, with the first retrieving lab results and the second focusing on the Covid-19 numbers.
The application for lab results is in QlikView and presents aggregated results in graphical elements in a simple and understandable way. The Covid-19 report, which is sent out from NPrinting, shows the number of positive tests and hospital admissions, the number in intensive care, etc.
The applications enable Lovisenberg Diakonale Sykehus to save time on manual registration and counting, as the numbers are now automatically extracted from the application in QlikView. In the future, the application can also be used for reporting and analysis of other disease progressions. This way, Lovisenberg Diakonale Sykehus can benefit from the application even after Covid-19.